An estimated 130,000 Hoosiers over the age of 60 using Medicaid will receive notices in early 2024 advising them to choose a Managed Care Entity to coordinate their health coverage.
Indiana’s largest teacher’s union is calling for better collective bargaining, increased pay for support staff and more say over curriculum in the upcoming legislative session.
In March, Eskenazi Health launched a fundraising campaign to help it move the needle on health disparities. As of last month, its foundation had raised $57 million.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
Smith said he would prioritize bipartisanship, “balance” and “dialogue,” and was also clear in calling himself a “pro-life conservative” and “pro-school choice.”
The EPA says it is not imposing an EV mandate, but Republicans say the plan favors EVs and punishes gas engines, forcing Americans into cars and trucks they can’t afford.
As one of the top mid-major conferences in the country, [the Horizon League] is affected by every single one of these seismic changes, even if that impact isn’t always direct.
The U.S. Department of Agriculture has ruled that farmers can begin trials on genetically modified corn plants developed by an ag-tech startup in the Hamilton County town of Atlanta.
From Mount Vernon to Michigan City and Morocco to Monroeville, cities and towns are creating unique solutions to challenges we could all learn and benefit from. Let’s empower our communities to be the laboratories for the state and create positive change for all Hoosiers.
Legislators’ efforts to improve student literacy and career readiness could end up fruitless if the state can’t solve another issue plaguing schools: Hoosier kids aren’t showing up to the classroom.
The Minority Business Development Agency is one of several federal programs under siege over a fundamental assumption ingrained in Washington policy: that certain racial and ethnic groups are inherently disadvantaged
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
